Xin Lang Cai Jing·2025-09-05 03:28Core Viewpoint - 康龙化成's stock has shown a positive trend with a year-to-date increase of 18.78%, reflecting strong market interest and performance in the biopharmaceutical sector [1][2]. Financial Performance - As of June 30, 康龙化成 reported a revenue of 64.41 billion yuan for the first half of 2025, representing a year-on-year growth of 14.93% [2]. - The company's net profit attributable to shareholders was 7.01 billion yuan, which is a decrease of 37.00% compared to the previous period [2]. Stock Market Activity - On September 5, 康龙化成's stock price rose by 2.16%, reaching 30.29 yuan per share, with a trading volume of 5.46 billion yuan and a turnover rate of 1.29% [1]. - The total market capitalization of 康龙化成 is 538.62 billion yuan [1]. - The stock has experienced a 0.10% increase over the last five trading days, a 6.65% increase over the last 20 days, and a 22.93% increase over the last 60 days [1]. Shareholder Information - As of June 30, 康龙化成 had 87,900 shareholders, an increase of 10.12% from the previous period [2]. - The top ten circulating shareholders include 中欧医疗健康混合A, which holds 63.40 million shares, and 香港中央结算有限公司, which increased its holdings by 14.86 million shares [3]. Business Overview - 康龙化成 specializes in drug research, development, and production services, with its main revenue sources being laboratory services (60.43%), CMC services (21.58%), clinical research services (14.58%), and other services [1]. - The company operates within the medical and biopharmaceutical industry, focusing on medical research outsourcing [1].